452 related articles for article (PubMed ID: 29801875)
21. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
22. Interventional closure vs. medical therapy of patent foramen ovale for secondary prevention of stroke: updated meta-analysis.
Vukadinović D; Schirmer SH; Vukadinović AN; Ukena C; Scheller B; Mahfoud F; Böhm M
Clin Res Cardiol; 2019 Feb; 108(2):157-166. PubMed ID: 30051178
[TBL] [Abstract][Full Text] [Related]
23. Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials.
Garg A; Thawabi M; Rout A; Sossou C; Cohen M; Kostis JB
Cardiology; 2019; 144(1-2):40-49. PubMed ID: 31574522
[TBL] [Abstract][Full Text] [Related]
24. Net clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: Meta-analysis and meta-regression of randomized trials.
Pasceri V; Pelliccia F; Bressi E; Mantione L; Gaudio C; Speciale G; Mehran R; Dangas GD; Patti G
Int J Cardiol; 2018 Sep; 266():75-80. PubMed ID: 29887476
[TBL] [Abstract][Full Text] [Related]
25. Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis.
Ntaios G; Papavasileiou V; Sagris D; Makaritsis K; Vemmos K; Steiner T; Michel P
Stroke; 2018 Feb; 49(2):412-418. PubMed ID: 29335335
[TBL] [Abstract][Full Text] [Related]
26. Transcatheter closure of patent foramen ovale for secondary prevention of ischemic stroke: Quantitative synthesis of pooled randomized trial data.
Hakeem A; Cilingiroglu M; Katramados A; Boudoulas KD; Iliescu C; Gundogdu B; Marmagkiolis K
Catheter Cardiovasc Interv; 2018 Nov; 92(6):1153-1160. PubMed ID: 29332308
[TBL] [Abstract][Full Text] [Related]
27. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
[TBL] [Abstract][Full Text] [Related]
28. Patent foramen ovale closure or medical therapy for secondary prevention of cryptogenic stroke: An update meta-analysis of randomized controlled trials.
Ma Y; Li D; Bai F; Qin F; Li J; Li Y; Liu N; Xie H; Zhou S; Liu Q
Medicine (Baltimore); 2018 Aug; 97(34):e11965. PubMed ID: 30142823
[TBL] [Abstract][Full Text] [Related]
29. Closure versus Medical Therapy for Patent Foramen Ovale in Patients with Cryptogenic Stroke: An Updated Meta-Analysis of Randomized Controlled Trials.
Qiu B; Cai Y; Wang D; Lin J; Fan Y
J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3463-3472. PubMed ID: 30185398
[TBL] [Abstract][Full Text] [Related]
30. Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses.
Udell JA; Opotowsky AR; Khairy P; Silversides CK; Gladstone DJ; O'Gara PT; Landzberg MJ
Can J Cardiol; 2014 Oct; 30(10):1216-24. PubMed ID: 25154803
[TBL] [Abstract][Full Text] [Related]
31. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.
Stortecky S; da Costa BR; Mattle HP; Carroll J; Hornung M; Sievert H; Trelle S; Windecker S; Meier B; Jüni P
Eur Heart J; 2015 Jan; 36(2):120-8. PubMed ID: 25112661
[TBL] [Abstract][Full Text] [Related]
32. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
[TBL] [Abstract][Full Text] [Related]
33. Percutaneous Closure Versus Medical Treatment in Stroke Patients With Patent Foramen Ovale: A Systematic Review and Meta-analysis.
De Rosa S; Sievert H; Sabatino J; Polimeni A; Sorrentino S; Indolfi C
Ann Intern Med; 2018 Mar; 168(5):343-350. PubMed ID: 29310133
[TBL] [Abstract][Full Text] [Related]
34. Secondary prevention of cryptogenic stroke in patients with patent foramen ovale: a systematic review and meta-analysis.
Fiorelli EM; Carandini T; Gagliardi D; Bozzano V; Bonzi M; Tobaldini E; Comi GP; Scarpini EA; Montano N; Solbiati M
Intern Emerg Med; 2018 Dec; 13(8):1287-1303. PubMed ID: 30032341
[TBL] [Abstract][Full Text] [Related]
35. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
[TBL] [Abstract][Full Text] [Related]
36. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
37. Patent foramen ovale closure versus medical therapy after cryptogenic stroke: An updated meta-analysis of all randomized clinical trials.
Kheiri B; Abdalla A; Osman M; Ahmed S; Hassan M; Bachuwa G
Cardiol J; 2019; 26(1):47-55. PubMed ID: 29512097
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy after closure of patent foramen ovale for ischemic neurological events in young adults: A systematic review and meta-analysis.
Xu L; Pan X; Zhou C; Li J; Wang F
Medicine (Baltimore); 2020 Jan; 99(2):e18675. PubMed ID: 31914059
[TBL] [Abstract][Full Text] [Related]
39. A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke.
Kasner SE; Sondergaard L; Nakum M; Gomez Montero M; Hashim M; Landaas EJ
J Med Econ; 2024; 27(1):337-343. PubMed ID: 38373018
[TBL] [Abstract][Full Text] [Related]
40. Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials.
Riaz H; Khan MS; Schenone AL; Waheed AA; Khan AR; Krasuski RA
Am Heart J; 2018 May; 199():44-50. PubMed ID: 29754665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
